13 November 2026

Ms Renee Hutchens
Senior Adviser Listings Supervision (Sydney)
39 Martin Place
SYDNEY, NSW 2000

By email: tradinghaltssydney@asx.com.au

Request for a trading halt

Actinogen Medical Limited ACN 086 778 476 (ASX: ACW) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

Pursuant to ASX Listing Rule 17.1, the Company requests the trading halt to enable a review and analysis of the clinical trial results for the XanaMIA phase 2b/3 trial.

We anticipate that the trading halt will be required until the earlier of the release of a material announcement or no later than 10.00 am AEDT on Tuesday, 17 November 2026.

The Company is not aware of any reason why the trading halt should not be granted by ASX Limited.

The Company is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely

Peter Webse
Company Secretary

Authorised by the Board of Actinogen Medical